Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

Antonio García-Gómez(Institut d'Investigació Biomédica de Bellvitge), Esteban Ballestar(Institut d'Investigació Biomédica de Bellvitge)
Nature Communications
January 18, 2021
10.1038/s41467-020-20715-x
Cited by 54

Related Papers

A DNA methylation fingerprint of 1628 human samples
|Genome Research|2011|418
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling
|Blood|2008|145
IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation
|Genome biology|2016|124
Understanding the Relevance of DNA Methylation Changes in Immune Differentiation and Disease
|Genes|2020|84
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
|PLoS ONE|2012|78